Rafferty Asset Management’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $479K | Sell |
83,821
-33,193
| -28% | -$151K | ﹤0.01% | 907 |
|
|
2026
Q1 | $527K | Sell |
117,014
-32,215
| -22% | -$168K | ﹤0.01% | 880 |
|
|
2025
Q4 | $918K | Buy |
149,229
+36,444
| +32% | +$264K | ﹤0.01% | 817 |
|
|
2025
Q3 | $815K | Sell |
112,785
-163
| -0.1% | -$968 | ﹤0.01% | 834 |
|
|
2025
Q2 | $600K | Sell |
112,948
-33,856
| -23% | -$200K | ﹤0.01% | 850 |
|
|
2025
Q1 | $1.3M | Sell |
146,804
-19,334
| -12% | -$232K | 0.01% | 682 |
|
|
2024
Q4 | $2.28M | Buy |
166,138
+55,690
| +50% | +$1.03M | 0.01% | 620 |
|
|
2024
Q3 | $3.03M | Buy |
110,448
+16,992
| +18% | +$460K | 0.01% | 534 |
|
|
2024
Q2 | $2.29M | Sell |
93,456
-155,747
| -62% | -$3.42M | 0.01% | 605 |
|
|
2024
Q1 | $5.31M | Buy |
249,203
+77,804
| +45% | +$1.67M | 0.02% | 464 |
|
|
2023
Q4 | $3.28M | Sell |
171,399
-37,085
| -18% | -$642K | 0.01% | 536 |
|
|
2023
Q3 | $3.34M | Buy |
208,484
+12,232
| +6% | +$233K | 0.02% | 477 |
|
|
2023
Q2 | $4.55M | Buy |
196,252
+26,411
| +16% | +$576K | 0.03% | 436 |
|
|
2023
Q1 | $3.95M | Sell |
169,841
-36,492
| -18% | -$741K | 0.03% | 437 |
|
|
2022
Q4 | $2.99M | Buy |
206,333
+35,049
| +20% | +$653K | 0.03% | 485 |
|
|
2022
Q3 | $3.27M | Buy |
171,284
+62,482
| +57% | +$1.43M | 0.03% | 405 |
|
|
2022
Q2 | $1.98M | Sell |
108,802
-22,185
| -17% | -$461K | 0.02% | 466 |
|
|
2022
Q1 | $3.3M | Sell |
130,987
-45,935
| -26% | -$1.18M | 0.02% | 485 |
|
|
2021
Q4 | $4.88M | Buy |
176,922
+83,152
| +89% | +$2.41M | 0.03% | 396 |
|
|
2021
Q3 | $3.03M | Buy |
93,770
+6,032
| +7% | +$200K | 0.02% | 476 |
|
|
2021
Q2 | $2.68M | Sell |
87,738
-19,614
| -18% | -$567K | 0.02% | 548 |
|
|
2021
Q1 | $3.27M | Buy |
107,352
+86,871
| +424% | +$2.47M | 0.02% | 432 |
|
|
2020
Q4 | $405K | Sell |
20,481
-60,067
| -75% | -$970K | ﹤0.01% | 733 |
|
|
2020
Q3 | $1.05M | Buy |
80,548
+27,510
| +52% | +$348K | 0.01% | 573 |
|
|
2020
Q2 | $601K | Buy |
53,038
+42,940
| +425% | +$610K | 0.01% | 667 |
|
|
2020
Q1 | $145K | Sell |
10,098
-75,659
| -88% | -$1.6M | 0.01% | 544 |
|
|
2019
Q4 | $2.33M | Sell |
85,757
-56,088
| -40% | -$1.54M | 0.04% | 334 |
|
|
2019
Q3 | $4.06M | Sell |
141,845
-27,107
| -16% | -$790K | 0.06% | 180 |
|
|
2019
Q2 | $4.69M | Buy |
168,952
+22,262
| +15% | +$629K | 0.08% | 178 |
|
|
2019
Q1 | $4.87M | Buy |
+146,690
| New | +$4.47M | 0.08% | 142 |
|
|
2018
Q4 | – | Sell |
-17,518
| Closed | -$806K | – | 687 |
|
|
2018
Q3 | $806K | Buy |
+17,518
| New | +$779K | 0.01% | 493 |
|
|
2017
Q2 | – | Sell |
-126,205
| Closed | -$2.42M | – | 581 |
|
|
2017
Q1 | $2.42M | Buy |
+126,205
| New | +$2.24M | 0.05% | 184 |
|
Other funds holding MYGN
VPC
Rafferty Asset Management's MYGN Position: Q2 2026 in Review
Rafferty Asset Management reduced its Myriad Genetics (MYGN) stake by 28% in Q2 2026, selling an estimated $151K and leaving 83,821 shares worth $479K. The position accounts for ﹤0.01% of the portfolio, ranked #907.
Rafferty Asset Management first reported a position in MYGN in Q1 2017 and has held it in 32 quarters since. The position peaked at $5.31M in Q1 2024. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.
- Rafferty Asset Management held 83,821 shares of Myriad Genetics worth $479K as of Q2 2026.
- Rafferty Asset Management sold 33,193 Myriad Genetics shares in Q2 2026, an estimated $151K.
- Myriad Genetics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #907 holding.
- Rafferty Asset Management first reported a position in Myriad Genetics in Q1 2017 and has held it in 32 quarters since.
- Rafferty Asset Management's Myriad Genetics position peaked at $5.31M in Q1 2024.
- 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.
Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.